Literature DB >> 9618773

Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations.

I M Longini1, K Sagatelian, W N Rida, M E Halloran.   

Abstract

Vaccination can have important indirect effects on the spread of an infectious agent by reducing the level of infectiousness of vaccinees who become infected. To estimate the effect of vaccination on infectiousness, one typically requires data on the contacts between susceptible and infected vaccinated and unvaccinated people. As an alternative, we propose a trial design that involves multiple independent and interchangeable populations. By varying the fraction of susceptible people vaccinated across populations, we obtain an estimate of the reduction infectiousness that depends only on incidence data from the vaccine and control groups of the multiple populations. One can also obtain from these data an estimate of the reduction of susceptibility to infection. We propose a vaccination strategy that is a trade-off between optimal estimation of vaccine efficacy for susceptibility and of vaccine efficacy for infectiousness. We show that the optimal choice depends on the anticipated efficacy of the vaccine as well as the basic reproduction number of the underlying infectious disease process. Smaller vaccination fractions appear desirable when vaccine efficacy is likely high and the basic reproduction number is not large. This strategy avoids the potential for too few infections to occur to estimate vaccine efficacy parameters reliably.

Entities:  

Mesh:

Year:  1998        PMID: 9618773     DOI: 10.1002/(sici)1097-0258(19980530)17:10<1121::aid-sim824>3.0.co;2-e

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  14 in total

Review 1.  Vaccine trials.

Authors:  C P Farrington; E Miller
Journal:  Mol Biotechnol       Date:  2001-01       Impact factor: 2.695

2.  Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety.

Authors:  S M Blower; K Koelle; D E Kirschner; J Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  Mathematical model comparisons of potential non-typeable Haemophilus influenzae vaccine effects.

Authors:  Ximin Lin; James S Koopman; Stephen E Chick
Journal:  J Theor Biol       Date:  2006-10-06       Impact factor: 2.691

4.  Critical immune and vaccination thresholds for determining multiple influenza epidemic waves.

Authors:  Laura Matrajt; Ira M Longini
Journal:  Epidemics       Date:  2011-12-07       Impact factor: 4.396

5.  Estimating sibling spillover effects with unobserved confounding using gain-scores.

Authors:  David C Mallinson; Felix Elwert
Journal:  Ann Epidemiol       Date:  2022-01-03       Impact factor: 3.797

6.  Large sample randomization inference of causal effects in the presence of interference.

Authors:  Lan Liu; Michael G Hudgens
Journal:  J Am Stat Assoc       Date:  2014-01-01       Impact factor: 5.033

7.  Spillover effects in epidemiology: parameters, study designs and methodological considerations.

Authors:  Jade Benjamin-Chung; Benjamin F Arnold; David Berger; Stephen P Luby; Edward Miguel; John M Colford; Alan E Hubbard
Journal:  Int J Epidemiol       Date:  2018-02-01       Impact factor: 7.196

8.  Vaccination Programs for Endemic Infections: Modelling Real versus Apparent Impacts of Vaccine and Infection Characteristics.

Authors:  Romain Ragonnet; James M Trauer; Justin T Denholm; Nicholas L Geard; Margaret Hellard; Emma S McBryde
Journal:  Sci Rep       Date:  2015-10-20       Impact factor: 4.379

9.  Integrating Transgenic Vector Manipulation with Clinical Interventions to Manage Vector-Borne Diseases.

Authors:  Kenichi W Okamoto; Fred Gould; Alun L Lloyd
Journal:  PLoS Comput Biol       Date:  2016-03-10       Impact factor: 4.475

Review 10.  Estimating influenza vaccine efficacy from challenge and community-based study data.

Authors:  Nicole E Basta; M Elizabeth Halloran; Laura Matrajt; Ira M Longini
Journal:  Am J Epidemiol       Date:  2008-10-29       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.